SMC
MRTX

Smith, Moore & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Smith, Moore & Co’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,000
Closed -$210K – 387
2022
Q3 		$210K Hold
3,000
– – 0.03% 346
2022
Q2 		$201K Buy
+3,000
New +$191K 0.03% 359
2022
Q1 		– Sell
-2,000
Closed -$293K – 438
2021
Q4 		$293K Buy
2,000
+500
+33% +$77.6K 0.04% 331
2021
Q3 		$265K Buy
+1,500
New +$241K 0.04% 334

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Smith, Moore & Co's MRTX Position: Q4 2022 in Review

Smith, Moore & Co sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 3,000 shares — an estimated $210K sold.

Smith, Moore & Co first reported a position in MRTX in Q3 2021 and held it in 4 quarters. The position peaked at $293K in Q4 2021. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

  • Smith, Moore & Co reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Smith, Moore & Co sold 3,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $210K.
  • Smith, Moore & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • Smith, Moore & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $293K in Q4 2021.
  • 233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Smith, Moore & Co's 13F filing for Q4 2022, filed 13 Feb 2023.